Neovacs Reduces Costs by 70% and Secures Financing Plan Through 2026
The biopharmaceutical company Neovacs announces the implementation of its drastic cost reduction plan and the establishment of a scheduled financing calendar to ensure visibility over its cash flow needs. The recurring monthly financing need has been reduced from nearly €700k to about €200k.
Strategic Restructuring and Continued Research
Neovacs has implemented a restructuring plan focused on three main areas: continuing active immunotherapy research programs to regulate the overproduction of proteins such as IL-4/IL-13/IgE and on the production of innovative lipids, in collaboration with academic laboratories and partners; significant reduction of fixed costs through a social plan adapted to the new strategy; and seeking partners to enhance the value of the product portfolio under development. These measures aim to preserve the company's scientific assets.
Scheduled Financing Calendar Established
Neovacs has set up a scheduled financing calendar with monthly draws of 250 OCEANE-BSA, with a nominal value of €10,000 each, starting from April 2026 until December 2026, for a cumulative amount of €2.25 million. The identified mobilizable resources, amounting to approximately €17 million, include gross cash, the reimbursement of financial investments estimated at €5.9 million as of December 31, 2025, and the refinancing of real estate assets estimated at more than €10 million. The company also has a theoretical residual drawing capacity of €8.75 million on its financing contract established in September 2025.
